Biochem/physiol Actions

Cell permeable: no

Reversible: yes

Product does not compete with ATP.

Primary TargetACE

Target IC₅₀: 23-35 nM against angiotensin-converting enzyme (ACE); 11 µM against LTA4 hydrolase; ~ 320 nM inhibiting apoptosis in human lung epithelial cells

General description

An antihypertensive agent that competitively inhibits angiotensin-converting enzyme (ACE; IC₅₀= 23-35 nM) and acts as a reversible and competitive inhibitor of LTA₄ hydrolase (IC₅₀ = 11 µM). Inhibits angiogenesis and slows the growth of experimental tumors in rats. Reported to inhibit apoptosis in human lung epithelial cells (IC₅₀ = ~ 320 nM).

An antihypertensive agent. Reversible and competitive inhibitor of LTA₄ hydrolase (IC₅₀ = 11 µM). Also a competitive inhibitor of angiotensin-converting enzyme (ACE). Inhibits angiogenesis and slows the growth of experimental tumors in rats.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Uhal, B.D., et al. 1998. Am. J. Physiol.275, L1013.Volpert, O.V., et al. 1996. J. Clin. Invest.98, 671.Voors, A.A., et al. 1995. J. Cardiovasc. Risk2, 413.Orning, L., et al. 1991. J. Biol. Chem. 266, 16507.Kostis, J. 1988. Am. Heart J. 116, 1591.

Packaging

1 g in Plastic ampoule

Warning

Toxicity: Carcinogenic / Teratogenic (D)